1. Intracellular cholesterol biosynthesis in enchondroma and chondrosarcoma.
- Author
-
Zhang H, Wei Q, Tsushima H, Puviindran V, Tang YJ, Pathmanapan S, Poon R, Ramu E, Al-Jazrawe M, Wunder J, and Alman BA
- Subjects
- Animals, Cell Survival, Chondrocytes metabolism, Chondroma drug therapy, Chondroma genetics, Chondroma pathology, Chondrosarcoma drug therapy, Chondrosarcoma genetics, Chondrosarcoma pathology, Disease Models, Animal, Isocitrate Dehydrogenase genetics, Lovastatin pharmacology, Mice, Mice, Knockout, Xenograft Model Antitumor Assays, Cholesterol biosynthesis, Chondroma metabolism, Chondrosarcoma metabolism, Genetic Predisposition to Disease genetics
- Abstract
Enchondroma and chondrosarcoma are the most common benign and malignant cartilaginous neoplasms. Mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) are present in the majority of these tumors. We performed RNA-seq analysis on chondrocytes from Col2a1Cre;Idh1LSL/+ animals and found that genes implied in cholesterol synthesis pathway were significantly upregulated in the mutant chondrocytes. We examined the phenotypic effect of inhibiting intracellular cholesterol biosynthesis on enchondroma formation by conditionally deleting SCAP (sterol regulatory element-binding protein cleavage-activating protein), a protein activating intracellular cholesterol synthesis, in IDH1 mutant mice. We found fewer enchondromas in animals lacking SCAP. Furthermore, in chondrosarcomas, pharmacological inhibition of intracellular cholesterol synthesis significantly reduced chondrosarcoma cell viability in vitro and suppressed tumor growth in vivo. Taken together, these data suggest that intracellular cholesterol synthesis is a potential therapeutic target for enchondromas and chondrosarcomas.
- Published
- 2019
- Full Text
- View/download PDF